National Comprehensive Cancer Network-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013318)
◆英語タイトル:National Comprehensive Cancer Network - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013318
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:48
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
National Comprehensive Cancer Network (NCCN) is a contract research organization that offers clinical services. The organization offers research and medical information to help patients and health professionals related to cancer care. It provides subscriptions and products which include NCCN flash updates, NCCN drugs and biologic compendium, NCCN chemotherapy order templates, NCCN trends and NCCN academy video modules, among others. The organization’s research areas include oncology pre clinical, translation and clinical research. It offers services to patients, clinicians and health care decision-makers. NCCN is headquartered in Fort Washington, Pennsylvania, the US.

National Comprehensive Cancer Network – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
National Comprehensive Cancer Network, Medical Devices Deals, 2011 to YTD 2017 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 13
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 14
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 15
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 16
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 17
Bristol-Myers Squibb Enters into Research Agreement with NCCN 18
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 19
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute Form Joint Venture 20
Juno Therapeutics Enters into Research Agreement with FHCRC 21
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 22
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 23
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 24
Licensing Agreements 26
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 26
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 27
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 28
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Juno Therapeutics Enters into Licensing Agreement with FHCRC 31
National Comprehensive Cancer Network – Key Competitors 32
National Comprehensive Cancer Network – Key Employees 33
National Comprehensive Cancer Network – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Government and Public Interest 36
Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 36
Sep 27, 2017: Study Finds “Standard Care” Treatments in Breast Cancer Clinical Trials Not Always Standard 37
May 19, 2017: NCCN and Pfizer Address Quality Improvement in Breast Cancer through Clinical Pathways 38
Sep 26, 2016: NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms 39
Aug 29, 2016: New NCCN Imaging Appropriate Use Criteria Published for Eight Cancer Types 40
Apr 11, 2016: Helsinn Supports the Development of NCCN Guidelines For Patients on Nausea and Vomiting, with a Sponsorship Grant 41
Mar 21, 2016: Interventions Required to Reduce Non-Cancer-Related Hospitalizations for Elderly Men after Prostate Cancer Diagnosis, Study Finds 42
Feb 22, 2016: NCCN, in Collaboration With Pfizer, Awards 10 Grants for Provider Performance and Quality in Treatment of Metastatic Breast Cancer Initiatives 43
Feb 12, 2016: New NCCN Guidelines Include Evidence Blocks to Illustrate Value in Breast, Colon, Kidney, and Rectal Cancers 44
Product News 45
Jan 27, 2016: Groundbreaking Collaborative Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care With Big Data 45
Other Significant Developments 46
Oct 04, 2016: New NCCN Patient Resources Assist Decision-Making for People With Stomach Cancer 46
Mar 03, 2016: NCCN Publishes New Patient Education Resources for Patients with Chronic Lymphocytic Leukemia and Hodgkin Lymphoma—a Rare, Yet Curable, Blood Cancer 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Key Facts 2
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
National Comprehensive Cancer Network, Deals By Therapy Area, 2011 to YTD 2017 9
National Comprehensive Cancer Network, Medical Devices Deals, 2011 to YTD 2017 10
National Comprehensive Cancer Network, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Vir Biotechnology and Fred Hutchinson Cancer Research Center Enter into Research Agreement 13
Context Therapeutics Enters into Partnership with Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer 14
Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 15
BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 16
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 17
Bristol-Myers Squibb Enters into Research Agreement with NCCN 18
A1M Pharma Enters into Rresearch Agreement with Fred Hutchinson Cancer Research Centre 19
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 20
Juno Therapeutics Enters into Research Agreement with FHCRC 21
Blaze Bioscience Enters Into Agreement With Fred Hutchinson Cancer Research Center For Optides Discovery Program 22
Fred Hutchinson Cancer Research Center Enters Into Agreement With GlaxoSmithKline To Develop Drugs For Muscular Dystrophy 23
National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 24
Mustang Bio Enters into Licensing Agreement with Fred Hutchinson Cancer Research Center 26
Fred Hutchinson Cancer Research Center Enters into Licensing Agreement with Trianni 27
Actinium Pharma Enters Into Licensing Agreement With Fred Hutchinson Cancer Research Center For BC8 28
Nohla Therapeutics Enters into Licensing agreement with Fred Hutchinson Cancer Research Center 30
Juno Therapeutics Enters into Licensing Agreement with FHCRC 31
National Comprehensive Cancer Network, Key Competitors 32
National Comprehensive Cancer Network, Key Employees 33
National Comprehensive Cancer Network, Subsidiaries 35

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ National Comprehensive Cancer Network-製薬・医療分野:企業M&A・提携分析(National Comprehensive Cancer Network - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆